| scholarly article | Q13442814 |
| P50 | author | Henrik Gréen | Q38544926 |
| P2860 | cites work | mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy | Q27824862 |
| Genetic contribution to variable human CYP3A-mediated metabolism | Q28212042 | ||
| Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. | Q33366351 | ||
| Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia | Q35148088 | ||
| Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine | Q36031211 | ||
| Taxol: a novel investigational antimicrotubule agent | Q37593661 | ||
| Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer | Q40715119 | ||
| Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism | Q40760221 | ||
| Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. | Q40773486 | ||
| Identification of functionally variant MDR1 alleles among European Americans and African Americans | Q43705904 | ||
| Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles | Q43947585 | ||
| Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer | Q46958963 | ||
| Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples | Q47872729 | ||
| Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. | Q50641149 | ||
| ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. | Q50666167 | ||
| beta-Tubulin mutations in ovarian cancer using single strand conformation analysis-risk of false positive results from paraffin embedded tissues. | Q50762508 | ||
| Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. | Q51938857 | ||
| Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. | Q54588624 | ||
| P433 | issue | 6 | |
| P921 | main subject | paclitaxel | Q423762 |
| chemotherapy | Q974135 | ||
| pharmacogenomics | Q1152227 | ||
| P304 | page(s) | 671-674 | |
| P577 | publication date | 2008-06-01 | |
| P1433 | published in | Pharmacogenomics | Q15724625 |
| P1476 | title | Pharmacogenomics of importance for paclitaxel chemotherapy | |
| P478 | volume | 9 |
| Q33818738 | Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines. |
| Q45244167 | Evaluation of vitamin B12 effects on DNA damage induced by paclitaxel |
| Q37346198 | Pharmaco(epi)genomics in ovarian cancer |
| Q47241273 | Pharmacogenetics of response to neoadjuvant paclitaxel treatment for locally advanced breast cancer. |
| Q36216741 | The ABCB1 3435 T allele does not increase the risk of paclitaxel-induced neurotoxicity |
Search more.